Safety data sheet documentation for warfarin (CAS 81-81-2), compiled to REACH Annex II with classification read against the harmonised entry in CLP Annex VI (H360D, H330, H310, H300). Two options: a working draft sent by e-mail immediately, or a signed card issued within 72 hours of complete input. The item supplied is a document — MolGod.org does not sell, supply or ship chemical substances.
Free, and generated automatically from the sources listed on this page. No person has reviewed it, and it describes the substance in general — not your material, your process or your intended market.
Section 9 — physicochemical properties: 8 of 22 established.
We show what is established and name what is not. Classification and identity are complete on every card; section 9 is where public data is thin.
Identity, structure, physical and chemical properties, analytical data and the literature — every value with the source it came from and the date that source was read. The full record is in the data sections further down this page.
Identity CAS · EC · IUPAC · synonyms · molecular formula · molecular weight
Structure 2D · 3D · SMILES · InChI · InChIKey
Physical melting point · boiling point · density · vapour pressure · solubility
Chemical reactivity · stability · incompatible materials
Analytical spectra and methods where available
References literature, with DOI where a DOI exists
Identifier coverage is shown as a count, not as a quality rating. It tells you how well characterised this substance is in public data — which is a different question from how good it is, and a more useful one when you are deciding whether the documentation behind it can be defended.
This page sells the documentation for this substance, not the substance. Choose the level you need.
€0Audit the sheet you already haveSend us your existing sheet for this substance and we tell you what is wrong with it. One per company. If it turns out to be sound, you buy nothing.Start the free audit →
€49.99Working draftThe complete sixteen-section document, referenced, downloadable immediately after checkout. The right choice while the paperwork is still moving.
€249.99Signed cardThe same document reviewed and signed, issued within 72 hours of complete input — for the moment somebody official asks who stands behind it.
Documentation available for this substance: safety data sheet · CLP label · certificate of analysis on request · specification. Languages: the official language of your destination market, produced per card.
Grade, purity, physical form, packaging, minimum order and lead time are not shown, because MolGod does not supply the material — those are facts about a seller, and there is no seller on this page. They appear on storefronts we build for suppliers, where somebody can answer for them.
What a compliance officer checks, and where it sits in the document. The values themselves are in the regulatory sections further down.
Classification harmonised entry with index number where one exists; self-classification shown separately and labelled, never merged
Hazard statements the official text, in the page language
Precautionary statements combined statements reproduced whole, never split
Pictograms and signal word
Inventory status per jurisdiction, each stated individually
Restrictions entry and scope where one applies
Authorisation entry and sunset date where one applies
Candidate list status and the supply-chain duty it triggers
Transport entry per mode — road, sea, air
Exposure limits per country, each naming the act it comes from
Document status revision date and the amendment in force when issued
Fields with no established status say so. This page never states that no restrictions apply — absence from a dataset is not clearance, and a document that treats it as clearance is the most dangerous kind of document in this field.
A digital PDF safety data sheet in the sixteen-section structure of REACH Annex II (Regulation 1907/2006).
Substance identification, hazard classification, physicochemical, toxicological and ecological information, and regulatory references.
Classification read against the harmonised entry in CLP Annex VI where one exists for the substance.
A version number, a compilation date, and the source behind each value that carries one.
Delivery by e-mail. Nothing is shipped.
What this is not
Not a chemical substance, not a sample, not any physical goods.
Not a certification. No official certification scheme for safety data sheets exists in the European Union.
Not legal approval, and not a guarantee of compliance in any jurisdiction.
Not a substitute for your own regulatory assessment, nor for the safety data sheet supplied by the manufacturer or importer of the substance you actually hold.
Not adapted to a specific workplace, process or national annex unless you provide that information.
Where the available evidence does not support a value, the sheet states that the value is not established rather than estimating one. A field with no recorded source is marked as such.
What is in the buyer pack
Everything your compliance officer will ask for, in one file.
The product page as PDF — the record as published, so what you forward matches what you read.
The safety data sheet at your entitlement level — sixteen sections in the order set by REACH Annex II, for this substance, in the language you select.
The CLP label artwork — generated from the same classification as the sheet, so the two cannot disagree.
The specification, and the certificate of analysis where batch data exists.
sources.txt — every citation with the date it was read.
An explicit list of what we could not establish — fields marked unavailable rather than filled with an estimate. This is the honest part of the document and we do not hide it in a footnote.
Your European buyer is going to forward this to somebody who was not on the call. The pack exists so that what they forward is complete, self-explanatory and traceable — rather than four attachments and a sentence beginning “I think this is everything”.
These switch the language of this page. Single substances. Mixtures on enquiry. One document, one language — additional languages are priced separately. Every version, including the Chinese one, is written to EU law — (EC) No 1907/2006 (REACH) Annex II and (EU) 2020/878 — and translated from it. The Chinese version is a reference translation, not a legally valid document for the Chinese market: an SDS for China must be compiled separately to GB/T 16483 and GB/T 17519.
3D model Warfarin, CAS 81-81-2, molecular formula C19H16O4, molar mass 308.3 g/mol
Data transcribed from regulatory registers and technical literature, with the source and edition stated. It does not replace the supplier's safety data sheet. Fields without a recorded source are marked as such.
PubChem. National Center for Biotechnology Information (NIH/NLM), chemical compound database. ↗
applies to: Molecular formula · Molecular weight · Melting point · Boiling point · LogP (lipophilicity) · IUPAC name · SMILES · InChIKey
et al.. (2026). "Warfarin Patient Self-Management in the US Health Care System: A Nonrandomized Clinical Trial.". https://doi.org/10.1001/jamanetworkopen.2026.2627
et al.. (2026). "Warfarin-GPRP: Development and Evaluation of a Novel Warfarin-Based Peptide Conjugate for Enhanced Anticoagulant Activity.". https://doi.org/10.1021/acsomega.5c09582
et al.. (2026). "A Descriptive Analysis of Potential Warfarin-NSAID Interactions in Dental Prescribing in Minas Gerais, Brazil, 2011-2021.". https://doi.org/10.3390/healthcare14101326
(2026). "A reproducible rat model for warfarin studies: Prothrombin time assessment with minimal blood using the CoaguChek XS and determination of an effective warfarin dosage.". https://doi.org/10.17
et al.. (2026). "Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis.". https://doi.org/10.1186/s12959-026-00865-6
(2026). "Factors Affecting the Time in Therapeutic Range of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation.". https://doi.org/10.1177/10760296251414128
et al.. (2026). "Causal Effects of Atrial Fibrillation and Warfarin Use on Osteoporosis Risk: A Two-Sample Mendelian Randomization Analysis.". https://doi.org/10.1155/ijog/7863262
db:Europe PMC
et al.. (2026). "Warfarin Patient Self-Management in the US Health Care System: A Nonrandomized Clinical Trial.". https://doi.org/10.1001/jamanetworkopen.2026.2627 →
db:Europe PMC
et al.. (2026). "Warfarin-GPRP: Development and Evaluation of a Novel Warfarin-Based Peptide Conjugate for Enhanced Anticoagulant Activity.". https://doi.org/10.1021/acsomega.5c09582 →
db:Europe PMC
et al.. (2026). "A Descriptive Analysis of Potential Warfarin-NSAID Interactions in Dental Prescribing in Minas Gerais, Brazil, 2011-2021.". https://doi.org/10.3390/healthcare14101326 →
db:Europe PMC
(2026). "Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular Pathways". https://doi.org/10.20944/preprints202606.1173.v1 →
db:Europe PMC
(2026). "A reproducible rat model for warfarin studies: Prothrombin time assessment with minimal blood using the CoaguChek XS and determination of an effective warfarin dosage.". https://doi.org/10.17221/4/2026-vetmed →
db:Europe PMC
et al.. (2026). "Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis.". https://doi.org/10.1186/s12959-026-00865-6 →
db:Europe PMC
(2026). "Factors Affecting the Time in Therapeutic Range of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation.". https://doi.org/10.1177/10760296251414128 →
db:Europe PMC
et al.. (2026). "Causal Effects of Atrial Fibrillation and Warfarin Use on Osteoporosis Risk: A Two-Sample Mendelian Randomization Analysis.". https://doi.org/10.1155/ijog/7863262 →
db:Europe PMC
(2026). "Treatment Stability of Warfarin and Acenocoumarol in Patients With Mechanical Heart Valves and Atrial Fibrillation: A One-Year Cohort Study.". https://doi.org/10.5644/ama2006-124.497 →
db:Europe PMC
et al.. (2026). "Development of a Clinical Decision Support Chatbot to Improve Access to Dental Clinical Practice Guidelines for Warfarin-Treated Patients.". https://doi.org/10.3233/shti260895 →
db:Europe PMC
et al.. (2026). "Narrative Review of Management Strategies and Risk Mitigation for Gastrointestinal Bleeding in Atrial Fibrillation Patients Receiving Warfarin.". https://doi.org/10.1177/10760296251410932 →
db:Europe PMC
et al.. (2026). "Persimmon-induced excessive anticoagulation in a patient with mechanical heart valves receiving warfarin therapy: A case report.". https://doi.org/10.1097/md.0000000000047861 →
db:Europe PMC
et al.. (2026). "Warfarin-Durian interaction: A case study bridging clinical outcomes and metabolic profiling through metabolomics.". https://doi.org/10.1016/j.toxrep.2026.102232 →
db:doaj
Shota Torii, Tomoya Narita, Aya Torii-Goto et al.. (2026). "Prolongation of prothrombin time-international normalized ratio by concomitant use of warfarin and combination therapy with lenvatinib and pembrolizumab in a patient with renal cell carcinoma on dialysis: a case report". Journal of Pharmaceutical Health Care and Sciences. https://doi.org/10.1186/s40780-026-00598-8 →
db:doaj
Pitchapong Kositchaiwat, Ubonwan Sapoo, Nutthada Areepium et al.. (2026). "Factors Associated With Time in Therapeutic Range Among Thai Patients with Non-valvular Atrial Fibrillation Taking Warfarin: Development of AHfHDP Score". Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296261480894 →
db:Europe PMC
et al.. (2025). "Machine Learning for Warfarin Therapy: A Systematic Review.". https://doi.org/10.3390/ph18101544 →
db:Europe PMC
(2025). "Rebound warfarin toxicity presenting with spontaneous hemopericardium in cardiac tamponade: a case report.". https://doi.org/10.1186/s12245-025-01037-5 →
db:Europe PMC
(2025). "Warfarin-Linezolid Interaction: A Case of Severe Coagulopathy.". https://doi.org/10.1155/crdi/5132611 →
db:crossref
Sunil Kumar Das. (2024). "Knowledge of warfarin among patients on warfarin therapy, using anticoagulant knowledge assessment tool, in Patan Hospital". Journal of General Practice and Emergency Medicine of Nepal. https://doi.org/10.59284/jgpeman291 →
db:doaj
Dalia Ibrahim, Sohair Albakari, Mohamed Abdelbasit et al.. (2024). "Assessment of Quality of Life, Anxiety, And Depression Via WHOQOL-BREF, And HADS Among Egyptian Patients on Warfarin Therapy: A Cross-Sectional Study.". Zagazig University Medical Journal. https://doi.org/10.21608/zumj.2024.279308.3309 →
Regulatory status of the substance
This substance is subject to regulatory requirements: hazardous waste management (BDO — national rule, Poland). Details in the \"Regulatory Status (REACH/ECHA/CLP)\" section and on the SDS. Regulatory information — does not restrict purchase in this store.
🧮 Stoichiometry Calculator
🧪 Chemical Data
CAS Number
81-81-2
Molecular formula
C19H16O4
Molar mass
308.3 g/mol
IUPAC name (EN)
4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
SMILES
CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
InChIKey
PJVWKTKQMONHTI-UHFFFAOYSA-N
📚 Related literature (20 articles)
Matched automatically from public bibliographic databases by text similarity. Not curated for this substance, and not part of the safety data sheet.
National Institute of Standards and Technology. 2024. "NIST Chemistry WebBook, SRD 69." Gaithersburg, MD: NIST. Accessed 2025-01-01. ↗
Spectral Database for Organic Structure Determination (SDBS). 2024. National Institute of Advanced Industrial Science and Technology (AIST), Japan. Accessed 2025-01-01. ↗
Ulrich, Eldon L., Hideo Akutsu, John F. Doreleijers, Yoko Harano, Yannis E. Ioannidis, Jundong Lin, Miron Livny, et al. 2008. "BioMagResBank." Nucleic Acids Research 36 (D1): D402–D408. [DOI ↗]
Horai, Hisayuki, Masanori Arita, Shigehiko Kanaya, Yoshito Nihei, Tasuku Ikeda, Kazuhiro Suwa, Yuya Ojima, et al. 2010. "MassBank: A Public Repository for Sharing Mass Spectral Data for Life Sciences." Journal of Mass Spectrometry 45 (7): 703–714. [DOI ↗]
Linstrom, P.J., and W.G. Mallard, eds. 2024. NIST Chemistry WebBook, NIST Standard Reference Database Number 69. Gaithersburg, MD: National Institute of Standards and Technology. ↗
McDonald, M. Shane, Mike McAvoy, and Ajit Bhalerao. 1988. "JCAMP-DX: A Standard Form for Exchange of Infrared Spectra in Computer Readable Form." Applied Spectroscopy 42 (1): 151–162. [DOI ↗]
PubChem. 2024. "PubChem Compound Database." National Library of Medicine, National Institutes of Health. Accessed 2025-01-01. ↗
Spectra are fetched on demand from 9 sources. Each spectrum is stored in our database — the next time it is opened there are zero requests to the external API. Download JCAMP-DX / CSV / PNG for every spectrum without searching.
Type of data: Predicted (calculated by nmrshiftdb2, not measured) — inferred: the source file carries no deposited measurement Basis: the file returned by the NMRShiftDB search-or-predict service is a JCAMP-DX LINK block with spectrometer frequency 0, and its values match no deposited NMRShiftDB spectrum of this compound on record at MolGod.
⏳ Loading…
▶ Click to load spectrum
🔗 Source
About the downloads (Type of data: Predicted (calculated by nmrshiftdb2, not measured) — inferred: the source file carries no deposited measurement) JCAMP: the NMRShiftDB file as received (JCAMP-DX 5.01 text). It is a peak list: chemical shift in ppm. MolGod adds header lines stating the type of data; the values are unchanged. CSV: the same peak list in two columns. The second column repeats the shift value; it is not a signal intensity. Lines starting with # state the type of data. PNG: a picture of the plot above, with the type of data written on it. Use: where signals are expected or were reported (chemical shift positions). Not included or guaranteed: intensities, multiplicities, coupling constants, line shapes, and solvent or temperature unless stated. A predicted list is not a measurement and cannot serve as a reference spectrum for identity or purity testing. Downloads become active after Show.
Data is fetched once (JCAMP-DX parser) and stored in the plugin's local database. No duplicate downloads, no NIST queries on subsequent openings. Licences respected (only a deep link plus our own visualisation is published).
Data retrieved live from multiple sources (priority chain). JCAMP-DX / CSV / PNG available for download under each spectrum.
IR — Fourier-transform infrared
Loading IR — Fourier-transform infrared…
MS — Mass spectrometry (EI 70eV)
Loading MS — Mass spectrometry (EI 70eV)…
🧮 DFT vs experiment comparison (IR)
Overlay of the experimental IR spectrum on the theoretically calculated spectrum using the B3LYP/6-31G* method (scaling factor 0.9614, Scott & Radom 1996).
Experimental DFT (theoretical)
Full theoretical data (geometry, frequencies): NIST CCCBDB ↗
📚 Bibliography (Chicago)
Becke, Axel D. 1993. "Density-Functional Thermochemistry. III. The Role of Exact Exchange." Journal of Chemical Physics 98 (7): 5648–5652. Definition of the B3LYP functional.
Scott, Anthony P., and Leo Radom. 1996. "Harmonic Vibrational Frequencies: An Evaluation of Hartree–Fock, Møller–Plesset, Quadratic Configuration Interaction, Density Functional Theory, and Semiempirical Scale Factors." Journal of Physical Chemistry 100 (41): 16502–16513. Scaling factors for DFT (e.g., 0.9614 for B3LYP/6-31G*).
Merrick, Jeffrey P., Damian Moran, and Leo Radom. 2007. "An Evaluation of Harmonic Vibrational Frequency Scale Factors." Journal of Physical Chemistry A 111 (45): 11683–11700. An update to Scott & Radom — scale factors for newer DFT functionals.
Lee, Chengteh, Weitao Yang, and Robert G. Parr. 1988. "Development of the Colle-Salvetti Correlation-Energy Formula into a Functional of the Electron Density." Physical Review B 37 (2): 785–789. The LYP correlation — complements Becke 1993 for B3LYP.
Hehre, Warren J., Robert Ditchfield, and John A. Pople. 1972. "Self-Consistent Molecular Orbital Methods. XII. Further Extensions of Gaussian-Type Basis Sets." Journal of Chemical Physics 56 (5): 2257–2261. Definition of the 6-31G* basis set (split-valence + polarization).
Johnson, Russell D., III, ed. 2022. "NIST Computational Chemistry Comparison and Benchmark Database (CCCBDB)." NIST Standard Reference Database 101, Release 22. https://cccbdb.nist.gov. Benchmark for theoretical values — the fallback link in the widget.
Cramer, Christopher J. 2004. "Essentials of Computational Chemistry: Theories and Models." 2nd ed. Chichester: Wiley. A textbook on DFT methods and vibrational frequency calculations.
Jensen, Frank. 2017. "Introduction to Computational Chemistry." 3rd ed. Chichester: Wiley. Modern computational chemistry — basis sets and methods for vibrational spectra.
Foresman, James B., and Æleen Frisch. 2015. "Exploring Chemistry with Electronic Structure Methods." 3rd ed. Wallingford, CT: Gaussian, Inc. A practical Gaussian guide — IR + Raman + NMR from DFT.
🎓 Spectrum interpretation guide (for students)
Explanations of every band in the spectrum — why it appears where it does, and what it indicates about the structure.
IR (infrared) (10 peaks)
The IR (infrared) spectrum contains 10 structurally identified bands (out of 18 detected in total: 6 outside recognised ranges, 2 in recognised groups omitted due to the display limit). The analysis below explains what each one means structurally and why it appears in that particular range.
C–H bend (CH3, CH2 — methyl/methylene)CH3/CH2● high
Band "C–H bend (CH3, CH2 — methyl/methylene)" appears in cases: 1,454.0 cm⁻¹ (weak (w)). This is the stretching vibration of aliphatic sp³ C–H bonds. Present in virtually every organic compound with an alkyl chain.
C=C aromatic ring stretcharomatic● high
Band "C=C aromatic ring stretch" appears in cases: 1,606.0 cm⁻¹ (weak (w)). Aromatic C=C bands at 1450–1600 cm⁻¹ plus out-of-plane bands at 690–900 cm⁻¹ allow the substitution pattern (ortho/meta/para) to be determined.
C=O stretch (ketone, aldehyde)C=O● high
Band "C=O stretch (ketone, aldehyde)" appears in cases: 1,702.0 cm⁻¹ (weak (w)). A strong carbonyl band — its exact position indicates the group type: aldehyde ~1720, ketone ~1715, ester ~1740, amide ~1660.
Band "C–O stretch (alcohol/ether)" appears in cases: 1,198.0 cm⁻¹ (weak (w)), 1,278.0 cm⁻¹ (weak (w)), 1,294.0 cm⁻¹ (weak (w)). The functional group is identified based on its characteristic range (Pavia/Silverstein) — the precise physical mechanism depends on the nearest chemical neighbors.
C–H out-of-plane bend (aromatic substitution pattern)aromatic_sub● medium
Band "C–H out-of-plane bend (aromatic substitution pattern)" appears in cases: 694.0 cm⁻¹ (weak (w)), 758.0 cm⁻¹ (weak (w)). The functional group is identified based on its characteristic range (Pavia/Silverstein) — the precise physical mechanism depends on the nearest chemical neighbors.
📚 Bibliography (Chicago)
Field, Leslie D., Sev Sternhell, and John R. Kalman. 2013. "Organic Structures from Spectra." 5th ed. Chichester: Wiley. A student problem-set textbook (interpretation guide companion).
Williams, Dudley H., and Ian Fleming. 2008. "Spectroscopic Methods in Organic Chemistry." 6th ed. London: McGraw-Hill. A classic of narrative spectral interpretation — explains "why the peak is here".
Crews, Phillip, Jaime Rodríguez, and Marcel Jaspars. 2009. "Organic Structure Analysis." 2nd ed. New York: Oxford University Press. A workflow for multi-parameter structural interpretation.
McLafferty, Fred W., and František Tureček. 1993. "Interpretation of Mass Spectra." 4th ed. Mill Valley, CA: University Science Books. MS fragmentation mechanisms — McLafferty rearrangement, m/z 29 = CHO.
Reusch, William. 2013. "Virtual Textbook of Organic Chemistry: Spectroscopy." East Lansing, MI: Michigan State University. https://www2.chemistry.msu.edu/faculty/reusch/VirtTxtJml/Spectrpy/spectro.htm. An open educational guide to IR/NMR/MS/UV — ideal for explaining functional groups.
Hesse, Manfred, Herbert Meier, and Bernd Zeeh. 2007. "Spektroskopische Methoden in der organischen Chemie." 8th ed. Stuttgart: Thieme. The standard German textbook on spectral interpretation.
Lampman, Gary M., Donald L. Pavia, George S. Kriz, and James R. Vyvyan. 2010. "Spectroscopy." 4th ed. Belmont, CA: Cengage Learning. A workbook with integrated interpretive narratives.
Kalsi, P. S. 2010. "Spectroscopy of Organic Compounds." 6th ed. New Delhi: New Age International. A complete textbook on IR/NMR/MS/UV spectral interpretation.
🔎 Spectrum Search (JCAMP-DX)
Upload a JCAMP-DX file (.jdx, .dx, .jcm) — the system will calculate the cosine similarity against all spectra in the database and display the TOP 10 matches.
📚 Bibliography (Chicago)
McLafferty, Fred W., ed. 2018. Wiley Registry of Mass Spectral Data. 11th ed. Hoboken, NJ: Wiley. A reference MS library (~775k spectra).
Stein, Stephen E., and Donald R. Scott. 1994. "Optimization and Testing of Mass Spectral Library Search Algorithms for Compound Identification." Journal of the American Society for Mass Spectrometry 5 (9): 859–866. The cosine + dot-product algorithm of NIST MS Search.
McDonald, Robert S., and Paul A. Wilks Jr. 1988. "JCAMP-DX: A Standard Form for Exchange of Infrared Spectra in Computer Readable Form." Applied Spectroscopy 42 (1): 151–162. The JCAMP-DX specification (extended to 5.01 for NMR/MS).
McLafferty, Fred W., and František Tureček. 1993. "Interpretation of Mass Spectra." 4th ed. Mill Valley, CA: University Science Books. Cosine-similarity matching and MS fragmentation — the foundation of the search algorithm.
Sumner, Lloyd W., Alexander Amberg, Dave Barrett, Michael H. Beale, Richard Beger, Clare A. Daykin, Teresa W.-M. Fan, et al. 2007. "Proposed Minimum Reporting Standards for Chemical Analysis." Metabolomics 3 (3): 211–221. MSI Level 1-4 — confidence-level standards for spectral matching.
Stein, Stephen E. 1999. "An Integrated Method for Spectrum Extraction and Compound Identification from Gas Chromatography/Mass Spectrometry Data." Journal of the American Society for Mass Spectrometry 10 (8): 770–781. The AMDIS algorithm — deconvolution + library match (NIST).
Lindon, John C., George E. Tranter, and David W. Koppenaal, eds. 2017. "Encyclopedia of Spectroscopy and Spectrometry." 3rd ed. Amsterdam: Academic Press. Encyclopedia entries on spectral library searching.
Smith, Brian C. 2011. "Fundamentals of Fourier Transform Infrared Spectroscopy." 2nd ed. Boca Raton, FL: CRC Press. FT-IR and the JCAMP-DX format for transmission spectra.
Larkin, Peter. 2017. "Infrared and Raman Spectroscopy: Principles and Spectral Interpretation." 2nd ed. Amsterdam: Elsevier. Principles of IR/Raman library matching and peak preprocessing.
Structural properties
Loading structural data...
❓ Frequently asked questions (9)
What is Warfarin?
Warfarin (CAS 81-81-2) is a chemical compound with the molecular formula C19H16O4 and a molecular weight of 308.3 g/mol. The chemical data comes from PubChem (National Institutes of Health, USA).
Helpful?
What is the CAS number of Warfarin?
The CAS number for Warfarin is 81-81-2. A CAS Registry Number is the standard identifier for a chemical substance in scientific literature and in trade.
Helpful?
What is the chemical formula of Warfarin?
The molecular formula of Warfarin is C19H16O4. Its molecular weight is 308.3 g/mol.
Helpful?
What is the melting point of Warfarin?
The melting point of Warfarin is 161.
Helpful?
What is the boiling point of Warfarin?
The boiling point of Warfarin is 356.
Helpful?
What is the density of Warfarin?
The density of Warfarin is 1.4.
Helpful?
What are the physicochemical properties of Warfarin?
Physicochemical properties of Warfarin are available in the chemical data section on the product page.
Helpful?
Is Warfarin hazardous?
Warfarin is classified as hazardous (signal word: Danger); its pictograms and hazard statements are set out in section 2 of its safety data sheet. Read the safety data sheet before use and follow the handling precautions it states.
Helpful?
How should Warfarin be stored?
Warfarin should be stored as its safety data sheet directs \— typically in a dry, cool, well-ventilated place, away from heat and from materials it is incompatible with.
Helpful?
➕ Suggest a question
Download structure files
Molecular structure files from the PubChem database (NIH). Compatible with Avogadro, PyMOL, Jmol, and ChemDraw.
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
g/L ↔ molarity
c (mol/L) = (g/L) / MW
±0.1% (depends on MW precision)
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
mmol/L ↔ molarity
c (mol/L) = mmol/L × 10⁻³
Exact
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
Celsius ↔ Kelvin
T(K) = t(°C) + 273.15
±0.01 K (ITS-90 scale)
BIPM (Bureau International des Poids et Mesures) (2019)
Celsius ↔ Fahrenheit
T(°F) = T(°C) × 9/5 + 32
±0.1 °F
Thompson A, Taylor BN (2008)
density-corrected % ↔ molarity
c (mol/L) = (%w/w × ρ × 10) / MW, ρ in g/mL
±0.1% when ρ known to 3 decimals
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007)
📚 Bibliography (8 authoritative sources)
Thompson A, Taylor BN (2008). Guide for the Use of the International System of Units (SI). NIST Special Publication 811 · DOI: 10.6028/NIST.SP.811-2008 → Primary SI standard for US scientific usage
Cohen ER, Cvitaš T, Frey JG, Holmström B, Kuchitsu K, Marquardt R, Mills I, Pavese F, Quack M, Stohner J, Strauss HL, Takami M, Thor AJ (2007). Quantities, Units and Symbols in Physical Chemistry — The IUPAC Green Book. RSC Publishing, 3rd ed. · DOI: 10.1039/9781847557889 · ISBN: 978-0-85404-433-7 → Canonical IUPAC guide for chemistry quantities/units
BIPM (Bureau International des Poids et Mesures) (2019). The International System of Units (SI), 9th edition. BIPM · ↗ → International SI definitions (incl. redefined kilogram 2019)
ISO/IEC (2022). Quantities and units — Part 1: General. International Organization for Standardization — ISO 80000-1:2022 · ↗ → General rules for physical quantities and units
ISO/IEC (2019). Quantities and units — Part 9: Physical chemistry and molecular physics. International Organization for Standardization — ISO 80000-9:2019 · ↗ → Concentration / molality / amount-of-substance conventions
Tiesinga E, Mohr PJ, Newell DB, Taylor BN (2021). CODATA recommended values of the fundamental physical constants: 2018. Rev. Mod. Phys. 93(2):025010 · DOI: 10.1103/RevModPhys.93.025010 → Avogadro, gas constant, molar volume (2019 SI revision)
IUPAC (2019). Compendium of Chemical Terminology — the IUPAC Gold Book (online). IUPAC · DOI: 10.1351/goldbook → Definitions of mass fraction, molality, normality, ppm, activity
Mills IM, Cvitaš T, Homann K, Kallay N, Kuchitsu K (1988). Quantities, Units and Symbols in Physical Chemistry. Blackwell Scientific Publications, 1st ed. · ISBN: 0-632-01773-5 → Historical predecessor of IUPAC Green Book
Data limitations notice. The safety information on this page is for reference only and does not replace a full safety data sheet (SDS). Before using the product, consult the manufacturer's current safety data sheet and the GHS/CLP guidance. The CLP classification applies to the pure bulk substance, not to commercial formulations.
GHS/CLP classification — Regulation (EC) No 1272/2008 + UN GHS Rev. 9 (2021).
H372 — Causes damage to organs through prolonged or repeated exposure
H411 — Toxic to aquatic life with long lasting effects
🛡 Precautionary statements (P)
P203 — Obtain, read and follow all safety instructions before use
✓ Harmonised classification pursuant to Annex VI of the CLP Regulation (EC) 1272/2008 (official, binding classification). Index number: 607-056-00-0.
Reference (Chicago): European Chemicals Agency. "warfarin (ISO); 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one, Index No. 607-056-00-0." In Table 3 of Annex VI to Regulation (EC) No 1272/2008 (CLP Regulation), 23rd Adaptation to Technical Progress (harmonised list as of 2026-07-07). Helsinki: European Chemicals Agency, 2026. https://echa.europa.eu/information-on-chemicals/annex-vi-to-clp.
Translations: CLP Regulation (EC) 1272/2008, Annexes III and IV. Data: PubChem/NLM.
☢️ Toxicological data (IARC + EPA CTX)
🧬 IARC Carcinogen Classification
IARC classification:
No individual IARC entry for this CAS
No separate IARC monograph in the checked lists — this is NOT confirmation of a lack of carcinogenicity. Check the CLP/GHS classification (CMR / GHS section).
et al.. (2026). "Warfarin Patient Self-Management in the US Health Care System: A Nonrandomized Clinical Trial.". https://doi.org/10.1001/jamanetworkopen.2026.2627 [DOI]
et al.. (2026). "Warfarin-GPRP: Development and Evaluation of a Novel Warfarin-Based Peptide Conjugate for Enhanced Anticoagulant Activity.". https://doi.org/10.1021/acsomega.5c09582 [DOI]
et al.. (2026). "A Descriptive Analysis of Potential Warfarin-NSAID Interactions in Dental Prescribing in Minas Gerais, Brazil, 2011-2021.". https://doi.org/10.3390/healthcare14101326 [DOI]
(2026). "Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular Pathways". https://doi.org/10.20944/preprints202606.1173.v1 [DOI]
(2026). "A reproducible rat model for warfarin studies: Prothrombin time assessment with minimal blood using the CoaguChek XS and determination of an effective warfarin dosage.". https://doi.org/10.17221/4/2026-vetmed [DOI]
et al.. (2026). "Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis.". https://doi.org/10.1186/s12959-026-00865-6 [DOI]
(2026). "Factors Affecting the Time in Therapeutic Range of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation.". https://doi.org/10.1177/10760296251414128 [DOI]
et al.. (2026). "Causal Effects of Atrial Fibrillation and Warfarin Use on Osteoporosis Risk: A Two-Sample Mendelian Randomization Analysis.". https://doi.org/10.1155/ijog/7863262 [DOI]
(2026). "Treatment Stability of Warfarin and Acenocoumarol in Patients With Mechanical Heart Valves and Atrial Fibrillation: A One-Year Cohort Study.". https://doi.org/10.5644/ama2006-124.497 [DOI]
et al.. (2026). "Development of a Clinical Decision Support Chatbot to Improve Access to Dental Clinical Practice Guidelines for Warfarin-Treated Patients.". https://doi.org/10.3233/shti260895 [DOI]
et al.. (2026). "Narrative Review of Management Strategies and Risk Mitigation for Gastrointestinal Bleeding in Atrial Fibrillation Patients Receiving Warfarin.". https://doi.org/10.1177/10760296251410932 [DOI]
et al.. (2026). "Persimmon-induced excessive anticoagulation in a patient with mechanical heart valves receiving warfarin therapy: A case report.". https://doi.org/10.1097/md.0000000000047861 [DOI]
et al.. (2026). "Warfarin-Durian interaction: A case study bridging clinical outcomes and metabolic profiling through metabolomics.". https://doi.org/10.1016/j.toxrep.2026.102232 [DOI]
Shota Torii, Tomoya Narita, Aya Torii-Goto et al.. (2026). "Prolongation of prothrombin time-international normalized ratio by concomitant use of warfarin and combination therapy with lenvatinib and pembrolizumab in a patient with renal cell carcinoma on dialysis: a case report". Journal of Pharmaceutical Health Care and Sciences. https://doi.org/10.1186/s40780-026-00598-8 [DOI]
Pitchapong Kositchaiwat, Ubonwan Sapoo, Nutthada Areepium et al.. (2026). "Factors Associated With Time in Therapeutic Range Among Thai Patients with Non-valvular Atrial Fibrillation Taking Warfarin: Development of AHfHDP Score". Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296261480894 [DOI]
🚨 Emergency procedure — chemical spillToxic
CAS 81-81-2GHS:H360DH330H310H300H372H411⚠️ EVACUATION (10m)💨 Ventilation
🥽 PPE — Personal protective equipment
Goggles:Yes
Suit:lab coat
Respirator:SCBA (self-contained breathing apparatus) — EN 137:2006
📦 Small spill (<1L) — absorbent: inert mineral / HEPA-filter vacuum (for dusts)
⚠️ GENERIC procedure derived from the GHS classification (no curated data for this CAS). Always follow the supplier's current Safety Data Sheet (SDS).
1. Restrict access; ventilate.
2. Resistant PPE + respiratory protection (dust: P2/P3 half-mask; vapors: per SDS).
3. Collect mechanically into a sealed, labeled container; minimize dust/vapor generation.
4. Wash the area with water; treat residues and absorbent as hazardous waste.
Additional properties from GHS:
• health hazard (CMR / STOT / aspiration) — minimize exposure
• hazardous to the environment — prevent entry into drains, soil and water
🛢️ Large spill (>1L) ⚠️ Hazardous material
1. Evacuate; entry only in full PPE with respiratory protection.
2. Contain; avoid raising dust and dispersing the substance.
3. Collect mechanically into a labeled UN container; hand over to an authorized company (BDO — national rule, Poland).
4. Report the incident per the OHS procedure; on release to the environment notify the Regional Environmental Inspectorate (WIOŚ) (national rule — Poland).
🩹 First aid
🧴 Skin
1. Remove contaminated clothing.
2. Rinse the skin with plenty of water for ≥15 min.
3. The substance may be absorbed through the skin — monitor symptoms / see a doctor.
👁️ Eyes
1. Rinse with water for ≥15 min, eyelids held open; remove contact lenses.
2. See an ophthalmologist if irritation persists.
🫁 Inhalation
1. Move the casualty to fresh air, comfortable position.
2. If short of breath — oxygen / doctor.
🍽️ Ingestion
1. Rinse the mouth with water; do NOT induce vomiting.
2. Poison Control Center (Poland): +48 42 631 47 24.
🌍 Environment:
Water: High; Soil: Medium; ❌ Do not release into drains; Waste Code: 16 05 06*
📚 Scientific references (Chicago Author-Date) — 8
European Chemicals Agency (ECHA). 2020. Guidance on the Compilation of Safety Data Sheets — Section 6: Accidental Release Measures. ECHA.
[link ↗]
European Parliament and Council. 2008. Regulation (EC) No 1272/2008 (CLP) — Hazard classes and H-statements. Official Journal of the European Union L 353.
[link ↗]
National Institute for Occupational Safety and Health (NIOSH). 2023. Pocket Guide to Chemical Hazards — NIOSH Pocket Guide to Chemical Hazards. CDC.
[link ↗]
U.S. Occupational Safety and Health Administration. 2024. 29 CFR 1910.120 — Hazardous Waste Operations and Emergency Response (HAZWOPER). U.S. Code of Federal Regulations.
[link ↗]
National Fire Protection Association. 2018. NFPA 472: Standard for Competence of Responders to Hazardous Materials/Weapons of Mass Destruction Incidents. NFPA.
[link ↗]
European Parliament and Council. 2012. Directive 2012/18/EU on the Control of Major-Accident Hazards Involving Dangerous Substances (Seveso III). Official Journal of the European Union L 197: 1–37.
[link ↗]
U.S. National Institute for Occupational Safety and Health. 2024. NIOSH Pocket Guide to Chemical Hazards. Centers for Disease Control and Prevention.
[link ↗]
European Chemicals Agency. 2020. Guidance on the Compilation of Safety Data Sheets (SDS), Version 3.1. ECHA.
[link ↗]
Sources: GHS/CLP classification (PubChem/SDS) — generic fallback · ECHA Guidance on SDS (section 6) · NIOSH Pocket Guide.
Indicative data only — in an emergency, always follow the supplier's instructions and local occupational health and safety (OHS) regulations.
☠️ Visual PPE guide (personal protective equipment)Toxic
🧤 Gloves
Double nitrile (double-glove) >0.2 mm (each layer) EN 374-1 typ B
Replace every 30 min or immediately after contact
👁️ Safety Glasses / Goggles
EN 166 B
Full side protection; sealed goggles for toxic dusts
🥼 Lab Coat / Coverall
Full buttoned lab coat + disposable sleeves EN 13688
Airborne concentration < OEL (NDS) per Dz.U. 2024 item 1017
😷 Respirator Required
P2 half-mask (fine aerosols) or P3 (>10× OEL); full-face mask with A1B1E1K1-P3 filter for toxic organic vapors
📚 Scientific references (Chicago Author-Date)
European Committee for Standardization (CEN). 2016. EN 374-1:2016 — Protective gloves against dangerous chemicals and micro-organisms — Part 1: Terminology and performance requirements for chemical risks. CEN, Brussels. EN 374-1:2016. [link ↗] — Classification of chemical-resistant gloves type A/B/C; JKLPT permeation tests
European Committee for Standardization (CEN). 2001. EN 166:2001 — Personal eye-protection — Specifications. CEN, Brussels. EN 166:2001. [link ↗] — Markings: B = medium-energy impact, T = extreme temperatures, 9 = molten metals and hot solids
European Committee for Standardization (CEN). 2009. EN 14605:2005+A1:2009 — Protective clothing against liquid chemicals — Performance requirements for clothing with liquid-tight (Type 3) or spray-tight (Type 4) connections. CEN, Brussels. EN 14605:2009. [link ↗] — Type 3 (jet-tight) and Type 4 (spray-tight) protection against liquid chemicals
National Institute for Occupational Safety and Health (NIOSH). 2017. Recommendations for Chemical Protective Clothing: A Companion to the NIOSH Pocket Guide. U.S. Department of Health & Human Services / CDC. [link ↗] — Practical guide to CPC (chemical protective clothing) selection per substance and exposure scenario
Occupational Safety and Health Administration (OSHA). 2011. Personal Protective Equipment — General requirements. U.S. Department of Labor — 29 CFR 1910.132. 29 CFR 1910.132. [link ↗] — The employer must provide PPE + training + a documented written hazard assessment
ℹ️ Regulatory obligations checklist for CAS 81-81-2.
Status based on: ADR 2025 (Table A), REACH Annex XVII, CLP Annex VI (harmonised classification), hazard class from the m14-spill DB, SVHC, GIS and the Polish OEL list. Principle: no data = no claim (we do NOT declare "no restrictions" without a basis).
✅SDS (Safety Data Sheet) availablefulfilled
How to comply: Requirement: current SDS compliant with Reg. 1907/2006 (REACH) Annex II, 16-section format.
Legal basis: Regulation (EC) No 1907/2006 (REACH) Art. 31 + Annex II
▣Compliant CLP label (pictograms + signal word + H/P)required
How to comply: The label must include: GHS pictograms, the signal word (Danger/Warning), hazard (H) and precautionary (P) statements, and manufacturer details. Required since 2010 (substances) and 2015 (mixtures). For this substance a HARMONISED CLASSIFICATION applies (CLP Annex VI) — see below; it takes precedence over self-classification.
Legal basis: Regulation (EC) No 1272/2008 (CLP) Art. 17-33 + Annex VI (harmonised classification)
❓ADR transport (international agreement)to be verified
How to comply: No ADR data in the MOL-GOD dataset for this CAS number. Do NOT assume there are no restrictions — before shipping, verify the transport classification in ADR 2025 (Table A) and in section 14 of the safety data sheet (SDS).
Legal basis: ADR 2025 European Agreement + Polish Act of 19 August 2011 on the Transport of Dangerous Goods National rules — Poland
🔵REACH registration (>1 t/year EU import)conditional
How to comply: Importers/manufacturers ≥1 tonne/year must register the substance with ECHA (technical dossier + Chemical Safety Report if ≥10 t). Check the ECHA Annex VI / registered substances list.
Legal basis: Regulation (EC) No 1907/2006 (REACH) Art. 5-22
▣REACH Annex XVII (use/marketing restrictions)required
How to comply: Substance subject to a REACH Annex XVII restriction (entry 28–30): CMR category 1A/1B — not for supply to the general public (professional users only). Check the conditions for placing on the market/use and the note in SDS section 15.
Legal basis: Regulation (EC) No 1907/2006 (REACH) Annex XVII — restrictions on manufacture, placing on the market and use
⚠️ REACH Annex XVII (entry 28–30): CMR category 1A/1B — not for supply to the general public (professional users only).
European Parliament and Council. 2008. Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (CLP). Official Journal of the European Union L 353/1. CLP Regulation 1272/2008. [link ↗] — Classification, labelling and packaging of substances + mixtures (GHS implementation in the EU)
European Parliament and Council. 2006. Regulation (EC) No 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal of the European Union L 396/1. REACH Regulation 1907/2006. [link ↗] — REACH — registration, evaluation and authorisation of chemicals; SVHC; SDS Annex II
Ministerstwo Rodziny i Polityki Społecznej Rzeczypospolitej Polskiej. 2024. Rozporządzenie Ministra Rodziny i Polityki Społecznej z dnia 4 września 2024 r. w sprawie najwyższych dopuszczalnych stężeń i natężeń czynników szkodliwych dla zdrowia w środowisku pracy. Dziennik Ustaw RP 2024 poz. 1017. National rules — Poland[link ↗] — NDS and NDSCh for ~600 chemical substances — current Polish occupational exposure limits
United Nations Economic Commission for Europe (UNECE). 2025. European Agreement concerning the International Carriage of Dangerous Goods by Road (ADR), 2025 Edition. United Nations, Geneva. ADR 2025. [link ↗] — International agreement on the road transport of dangerous goods — UN numbers, classes, packaging
📚 Consolidated scientific references — Chicago Author-Date 10 sources
References collected from all Safety Hub tabs. CAS: 81-81-2 ·
PubChem ↗
Parlament Europejski i Rada UE. 2008. "Regulation (EC) nr 1272/2008 w sprawie klasyfikacji, oznakowania i pakowania substancji (CLP)." Dz.Urz. UE L 353. [↗]
GHS, Regulations
United Nations Economic Commission for Europe (UNECE). 2021. "Globally Harmonized System of Classification and Labelling of Chemicals (GHS), Ninth Revised Edition." United Nations, Geneva. [↗]
GHS
Goldfrank, Lewis R., Robert S. Hoffman, Mary Ann Howland, et al.. 2019. "Goldfrank's Toxicologic Emergencies, 11th ed.." McGraw-Hill Education, New York. ISBN 978-1-25-985961-8.
First aid, Toxicology
National Institute for Occupational Safety and Health (NIOSH). 2023. "NIOSH Pocket Guide to Chemical Hazards (DHHS Publ. 2005-149)." U.S. Department of Health and Human Services / CDC, Cincinnati, OH. [↗]
First aid, PPE, Toxicology
European Committee for Standardization (CEN). 2016. "EN 374-1:2016 — Protective gloves against dangerous chemicals and micro-organisms." CEN, Brussels. [↗]
PPE
UNECE. 2023. "European Agreement Concerning the International Carriage of Dangerous Goods by Road (ADR 2025)." United Nations, Geneva. [↗]
Disposal, Regulations
National Fire Protection Association (NFPA). 2022. "NFPA 400 — Hazardous Materials Code." NFPA, Quincy, MA. [↗]
Storage
Urben, P.G. (ed.). 2017. "Bretherick's Handbook of Reactive Chemical Hazards, 8th ed.." Butterworth-Heinemann / Elsevier, Oxford. [↗]
Storage
Ministerstwo Klimatu i Środowiska RP. 2023. "Baza danych o produktach i opakowaniach oraz o gospodarce odpadami (BDO)." Ministerstwo Klimatu i Środowiska, Warszawa. National rules — Poland[↗]
Disposal
International Agency for Research on Cancer (IARC / WHO). 2024. "IARC Monographs on the Identification of Carcinogenic Hazards to Humans — List of Classifications." WHO, Lyon. [↗]
Toxicology
Tabs with their own references (Emergency, PPE, Storage, Waste) contain additional bibliographic entries within their respective sections.
Paste a series of replicate measurements (CSV, or one number per line). The calculator computes the mean, standard deviation and 95% CI, and detects outliers (Grubbs + Dixon Q).
Separator: comma, space, tab, new line. Minimum 3 measurements.
📐 Statistical formulas
x̄ = Σxᵢ / n — arithmetic mean
s² = Σ(xᵢ - x̄)² / (n-1) — sample variance
s = √s² — standard deviation
RSD% = (s / x̄) × 100% — relative standard deviation
Plan your entire laboratory project: add experiments with reagents, replicates, and duration. You'll get a Gantt chart, a shopping list (with links to the store!), a budget with a 10% margin, and a GHS risk matrix.
💡 Log in to save projects.
Without logging in you can calculate but not save.
🧪 Solubility and solvent compatibility
Molecule
Warfarin
Formula
C19H16O4
logP (XLogP3)
2.70
Mass (g/mol)
308.3
Polarity
Hydrophobic (non-polar)
⚠️ GC estimate (Hoftyzer–Van Krevelen). No literature HSP data for this CAS — precision ±2 MPa½. Verify experimentally.
Solvent
Compat.
Ra
Visual
GC-MS
HPLC
Applications
References
Ra < R₀ = good miscibility · Ra < 1,5×R₀ = borderline · above = poor (R₀ — radius of the Hansen sphere of this molecule) For this molecule R₀ = 8..
Solubility theory (applied in compatibility prediction):
Yalkowsky, Samuel H., and Shri C. Valvani. 1980. "Solubility and Partitioning I: Solubility of Nonelectrolytes in Water." Journal of Pharmaceutical Sciences 69 (8): 912–922. https://doi.org/10.1002/jps.2600690814 — General Solubility Equation (GSE): logS = 0.5 − logP − 0.01(MP−25).
Hansen, Charles M. 2007. Hansen Solubility Parameters: A User's Handbook. 2nd ed. CRC Press. https://doi.org/10.1201/9781420006834 — HSP triplet (dD, dP, dH) + Ra formula.
Stefanis, E., and C. Panayiotou. 2008. "Prediction of Hansen Solubility Parameters with a New Group-Contribution Method." Int J Thermophys 29: 568–585. https://doi.org/10.1007/s10765-008-0415-z
Reichardt, Christian, and Thomas Welton. 2011. Solvents and Solvent Effects in Organic Chemistry. 4th ed. Wiley-VCH. https://doi.org/10.1002/9783527632220 — E_T(30) polarity scale, solvatochromism.
Snyder, Lloyd R., Joseph J. Kirkland, and John W. Dolan. 2010. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley. https://doi.org/10.1002/9780470508183 — Eluotropic series, polarity index.
Van Krevelen, D. W., and K. Te Nijenhuis. 2009. Properties of Polymers. 4th ed. Elsevier. https://doi.org/10.1016/B978-0-08-054819-7.X0001-5 — Hoftyzer–Van Krevelen group contribution for dD/dP/dH from SMILES.
Marcus, Yizhak. 1998. The Properties of Solvents. Wiley Series in Solution Chemistry, Vol. 4. ISBN 9780471983699 — Complete tabular set of 250+ solvents (ε, μ, donicity, acceptor numbers).
PubChem Compound Database — CAS 81-81-2 lookup ↗ — logP (XLogP3), water solubility experimental + predicted.
Full bibliography in the REFERENCES accordion (at the bottom of the page) — Chicago Manual of Style 17th ed., Author-Date.
🧮 Solubility calculator
Solubility:—
logS:—
Method:—
⚠️ —
Solubility vs temperature
🌐 Hansen Solubility Sphere (3D)
⚠️ The Hansen parameters for this substance fall outside the range of the method.
At least one of the δD/δP/δH parameters fell outside the domain of validity of the group contribution method (Hoftyzer–Van Krevelen), so the position of the molecule in Hansen space is unknown. The distance Ra is measured FROM THAT POINT — it cannot be calculated without knowing the point. The sphere and the distance table have been omitted rather than filled with numbers that have nothing behind them. Where a solubility measurement exists, it is shown in the table below.
Ra < R₀ = good miscibility · Ra < 1,5×R₀ = borderline · above = poor (R₀ — radius of the Hansen sphere of this molecule) Target molecule: δD=outside the method's range,
δP=outside the method's range,
δH=outside the method's range8
📊 Automatically extracted topics from the abstracts of 20 publications for CAS 81-81-2.
Algorithm: TF-IDF (Salton & Buckley 1988) — term frequency × inverse document frequency.
CAS, EC and molecular formula, resolved across the identifier systems a buyer uses. The count of systems resolved is shown, so you can see how well characterised this substance is rather than assuming.
Data
Every physicochemical value carries the source it came from and the date that source was read. Open any of them.
Classification
Read against the harmonised entry where one exists, with the index number stated. Self-classification is shown separately and labelled.
Regulatory
Inventory, restriction, authorisation and candidate-list status, each stated individually. Where a status is not established, this page says so — it never says no restrictions apply.
Documentation
Which documents exist, at what review level, in which languages, and when each was issued.
Supplier
Who is selling this, and what they have published about themselves.
Nothing on this page is a certification. It is a record you can audit.
Two guarantees, both with their limits stated
The Gap Report Guarantee
If the available evidence cannot support a defensible document for your CAS number and product specification, we will not invent the missing values. You receive a documented gap report and choose: a refund, store credit, or the report on its own.
A visible gap is worth more than a plausible number, because the plausible number is the one that fails when somebody checks it.
The Re-issue Promise
If a signed card is rejected by an authority or by a customer’s compliance officer on one of the points we checked and reported as passed, we re-issue it corrected at no charge and credit the original fee.
This covers the checks we performed and named. It does not cover registration status, tonnage, or your role in the supply chain — those are not ours to hold, and a guarantee that pretended otherwise would be worth nothing.
warfarin (ISO) — CAS 81-81-2, Annex VI index 607-056-00-0. Below: what the regulatory file for this substance must contain and where such files usually fail.
warfarin (CAS 81-81-2) at a glance
Substance – warfarin
CAS number – 81-81-2
EC number – 201-377-6 [1];226-907-3 [2];226-908-9 [3]
CLP Annex VI index number – 607-056-00-0
Also known as – 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
Hazard statements – H360D (may damage the unborn child); H330 (fatal if inhaled); H310 (fatal in contact with skin); H300 (fatal if swallowed); H372 (causes damage to organs through prolonged or repeated exposure); H411 (toxic to aquatic life with long lasting effects)
Concentration limits / M-factor / ATE – Repr. 1A;H360D: C ≥ 0.003%;STOT RE 1;H372: C ≥ 0.5%;STOT RE 2;H373: 0.05% ≤ C < 0.5%
Entry current as of – ATP09
CMR classification – yes, classified as carcinogenic, mutagenic or toxic for reproduction
Documentation issued – safety data sheet in REACH Annex II structure; working draft or signed card
What is supplied – a document. MolGod.org does not sell, supply or ship chemical substances.
Is warfarin (ISO) a controlled substance?
It is prescription-only in PL,US,EU,UK,CA,JP. None of this appears in the CLP classification, so a sheet built from Annex VI alone will be silent on it.
What is the EC number for warfarin (ISO)?
Alongside CAS 81-81-2, this substance carries EC number 201-377-6 [1];226-907-3 [2];226-908-9 [3] and Annex VI index 607-056-00-0. European documentation is built around the EC number as often as around the CAS: registration dossiers, the candidate list and customs systems key on it. A safety data sheet quoting only one of the two forces every downstream reader to look up the other.
How is warfarin (ISO) classified for road, sea and air transport?
Carriers and forwarders handling warfarin compare section 14 against the shipping papers before loading. Any disagreement stops the consignment at the point where correcting it is most expensive.
What is the CLP classification of warfarin (ISO)?
The harmonised classification for CAS 81-81-2 carries 6 hazard statements: H360D, H330, H310, H300, H372, H411. In plain terms this means may damage the unborn child; fatal if inhaled; fatal in contact with skin; fatal if swallowed. A harmonised entry is binding across the Union — an importer may not soften it, and a self-classification that diverges from it will not survive an enforcement check.
Which GHS pictograms apply to warfarin (ISO)?
The label for warfarin carries GHS06 (skull and crossbones), GHS08 (health hazard), GHS09 (environment), with the signal word Danger. These are not chosen by the supplier: CLP Annex VI states them for CAS 81-81-2, and the precedence rules in Annex I decide which pictogram is dropped when two would say the same thing. A label showing a different set from the register is wrong even if every hazard statement on it is correct.
Can I import warfarin (ISO) into the EU?
An import of CAS 81-81-2 is successful or unsuccessful based on whether the accompanying document matches the register entry. Among carboxylic acid esters, a common failure arises from classification carried over from a supplier outside the Union, where the same substance may be classified differently. The binding reference is index 607-056-00-0, and discrepancies occur in solvent and intermediate shipments.
Who is responsible for REACH compliance for warfarin (ISO)?
The responsibility for documentation accompanying warfarin (ISO) rests with the entity introducing it into the Union market, rather than with any external supplier. Importers share the same obligations as manufacturers, including designating a identifiable EU contact in section 1. A non-EU supplier may appoint a sole representative, but this appointment must be established prior to the movement of goods, not in response to subsequent inquiries.
Is warfarin (ISO) classified as a CMR substance?
CAS 81-81-2 is classified as a CMR substance (H360D). That status changes the obligations attached to every shipment: workplace exposure documentation, restrictions on supply to the general public, and substitution pressure from downstream users who must justify continued use. A safety data sheet for a CMR substance is read more closely than any other, because the classification itself invites scrutiny.
Identifiers that must agree
CAS 81-81-2 and index number 607-056-00-0 are not interchangeable and not decorative. The index number ties the entry to the harmonised classification; the CAS number ties it to the chemical literature. A file carrying one without the other forces every reader to reconstruct the link, and reconstruction is where errors enter.
What must the label for warfarin (ISO) contain?
The supply label for warfarin (ISO) is generated from the same classification that drives the safety data sheet: pictograms selected by precedence, one signal word derived from the highest hazard class present, and the hazard statements H360D, H330, H310… reproduced in full. Where the container is too small to carry the complete set at a legible size, there are lawful ways to handle it and unlawful ones that look identical to a non-specialist.
Other names for this substance
The same substance appears in trade and in the literature under several names: 4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one. A safety data sheet has to carry the name used in the harmonised entry, but a purchase order, a customs declaration and a certificate of analysis may each use a different one. Where the names diverge, CAS 81-81-2 is the identifier that reconciles them — and a document set that relies on trade names alone will eventually be read as describing three different materials.
What concentration limits apply to warfarin (ISO)?
The harmonised entry for warfarin carries specific concentration limits: H360D: C ≥ 0,003 %; H372 (blood): C ≥ 0,5 %; H373 (blood): 0,05 % ≤ C < 0,5 %. These override the generic cut-off values, so a mixture containing warfarin is classified against these figures and not against the default thresholds.
Where is regulatory status recorded for warfarin (ISO)?
Regulatory status for warfarin changes independently of its hazard classification. A substance can keep the same hazard profile for years and acquire new obligations in section 15, which is why that section dates faster than section 2.
Why a correct sheet stops being correct
Classification under CLP moves with each Adaptation to Technical Progress. A sheet for CAS 81-81-2 written before the amendment that touched its entry keeps stating a classification the register no longer holds. Nothing in the document announces this — it reads exactly as it did on the day it was issued, which is precisely why revision dates are checked before content.
What Annex VI notes and concentration limits apply to warfarin (ISO)?
The register also records Repr. 1A;H360D: C ≥ 0.003%;STOT RE 1;H372: C ≥ 0.5%;STOT RE 2;H373: 0.05% ≤ C < 0.5% for this entry. Specific concentration limits, M-factors and acute toxicity estimates override the generic cut-off values, so a mixture calculation that ignores them will classify the mixture wrongly in both directions.
Questions about documentation for warfarin
Is warfarin a CMR substance?
Yes. The harmonised classification places it among substances classified as carcinogenic, mutagenic or toxic for reproduction, which changes workplace documentation and supply restrictions.
What hazard statements apply to CAS 81-81-2?
The harmonised entry lists H360D, H330, H310, H300. These are binding across the Union and may not be softened by a self-classification.
In which language must the sheet be supplied?
In an official language of each Member State where warfarin is placed on the market, unless that State has stated otherwise.
Can I check whether my existing sheet is still valid?
Yes. A section-by-section reading against Annex II and the current harmonised entry establishes that in one pass, and a sheet that passes is reported as passing.
MolGod.org issues documentation and does not sell, supply or ship chemical substances. CAS 81-81-2 identifies the subject of this document.
Which version do you need?
📄
SDS Working Draft
€49.99
Delivered automatically after payment, by e-mail
Full 16-section REACH Annex II structure
Classification against ECHA CLP Annex VI
Public-source data with references
Unresolved gaps flagged, never filled by guesswork
For internal drafting and supplier review. Unsigned; supplier-specific fields may need completing.
Best for
Seeing what the document will contain before you commit
Comparing what a supplier sent you against the register
Finding the gaps in a sheet you already hold
Preparing an internal file before an export decision
Substances you handle but do not yet sell
Recommended when the document leaves your company✍
Expert-Reviewed SDS
€249.99
Everything in the Working Draft
Reviewed by a competent person under Annex II, section by section
Adapted to your company, product grade and identified use
Destination market and language checked
Transport section reviewed for the mode you request
Five rounds of corrections applied to your instructions
Within 72 hours of receiving complete input.
Best for
Any document that leaves your company
A customer or distributor who asked for the sheet
Paperwork travelling with an export shipment
A sheet an inspector or authority may read
Replacing a sheet a customer has already rejected
If you are unsure, read down the left column and stop at the first line that describes your situation.
What the document is for
Working Draft €49.99
Expert-Reviewed €249.99
Internal drafting and review
Yes
Yes
Checking a sheet a supplier sent you
Yes
Yes
Sent to your customer
Not written for this
Yes
Travels with an export shipment
Not written for this
Yes
Read by an inspector or authority
Not written for this
Yes
Adapted to your company, grade and identified use
No
Yes
Signed and dated by the reviewer
No
Yes
When you get it
Immediately after payment
Within 72 hours of complete input
Nothing stops you sending a draft to anyone. "Not written for this" means exactly that: it carries no signature and no fields adapted to your company, so it will not answer the questions the recipient is about to ask.
What the signature means
Who prepares the document
The document is generated by the MolGod engine from ECHA CLP Annex VI and the cited public sources, then read section by section by a qualified scientific reviewer with a degree in chemistry or a related scientific field.
What the review covers
The sheet is read section by section against the REACH Annex II structure. GHS classification and transport entries are checked against the sources cited in the document, and the sheet is adapted to the company, product grade and identified use you provide.
What is NOT verified
We do not test your material and we cannot confirm what is physically in your container: composition, concentration, impurities or manufacturing route. Those come from you and are reproduced as supplied.
What the signature is — and is not
The signature records that a qualified scientific reviewer read the document. It is not a government approval, not an ECHA approval, and not a legal certification — no such certification exists for safety data sheets in the EU. A signature does not by itself make a document legally valid or make your business compliant.
What you receive
A PDF in the 16-section REACH Annex II structure, signed and dated, with version information and a list of anything we could not establish. Five rounds of corrections are included.
Delivery
Within 72 hours of receiving complete input from you. The clock pauses whenever we are waiting on an answer.
Refunds
Full refund before review begins. If the evidence is insufficient, you choose a refund, store credit or a gap report. See the refund policy.
No fabricated-data guarantee.
If the available evidence is insufficient to support a defensible document for this CAS number and your product specification, we will not invent the missing values. You may choose a refund, store credit or a documented gap report.
The supplier placing the substance or mixture on the market remains responsible for ensuring that the final safety data sheet matches the material, its identified uses and their legal role in the supply chain.
📚 Scientific references (Chicago Author-Date) — click to expand
Batch management and laboratory certification standards — 13 independent sources (ICH Q1/Q3/Q6/Q7/Q10 + ISO 17025 + WHO TRS + 21 CFR 211 + EMA + USP + Ph.Eur. + PIC/S + IPEC-PQG).
International Council for Harmonisation (ICH). 2000. "Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients." ICH Expert Working Group. [link ↗] — GMP for APIs — adopted by EMA, FDA, MHLW
International Organization for Standardization. 2017. "ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories." ISO. [link ↗] — Lab accreditation standard underpinning every CoA
World Health Organization. 2010. "WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles (WHO Technical Report Series No. 957, Annex 3)." WHO Press. [link ↗] — WHO TRS No. 957 — global reference for GMP
International Council for Harmonisation (ICH). 2003. "ICH Q1A(R2): Stability Testing of New Drug Substances and Products." International Council for Harmonisation. [link ↗] — Source for batch shelf-life and retest dating
International Council for Harmonisation (ICH). 2006. "ICH Q3A(R2): Impurities in New Drug Substances." ICH. [link ↗]
International Council for Harmonisation (ICH). 1999. "ICH Q6A: Specifications for New Drug Substances and Products." ICH. [link ↗] — CoA acceptance-criteria specification standard
International Council for Harmonisation (ICH). 2008. "ICH Q10: Pharmaceutical Quality System." ICH. [link ↗]
U.S. Food and Drug Administration. 2024. "21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals." US Code of Federal Regulations. [link ↗] — US legal mandate (Subpart J — Records and Reports)
European Medicines Agency. 2014. "Guideline on Process Validation for Finished Products — Information and Data to Be Provided EMA/CHMP/CVMP/QWP/BWP/70278/2012." European Medicines Agency. [link ↗]
United States Pharmacopeial Convention. 2024. "United States Pharmacopeia and National Formulary, USP 47-NF 42." USP. [link ↗]
European Pharmacopoeia Commission. 2024. "European Pharmacopoeia 11th Edition." Council of Europe — EDQM. [link ↗]
Pharmaceutical Inspection Co-operation Scheme (PIC/S). 2021. "Guide to Good Manufacturing Practice for Medicinal Products PE 009-15." PIC/S Secretariat, Geneva. [link ↗] — Cross-recognized GMP for 54 inspectorates worldwide
International Pharmaceutical Excipients Council (IPEC) and Pharmaceutical Quality Group (PQG). 2017. "Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients." IPEC-Americas. [link ↗] — Excipient-grade CoA standard for non-API ingredients
⚠️ Drug interactions (15)
Known pharmacokinetic and pharmacodynamic interactions for CAS 81-81-2 according to consensus clinical sources. This information is educational — it does not replace medical consultation.
Mechanism: Synergistic inhibition of hemostasis: aspirin irreversibly acetylates platelet COX-1 (TXA2 ↓), warfarin blocks VKORC1 (factors II/VII/IX/X ↓). Aspirin additionally displaces warfarin from albumin (minimal effect).
Clinical effect: Significantly increased risk of gastrointestinal, intracranial and other bleeding.
Management: Avoid combining unless there is a cardiological indication. Monitor INR; consider a PPI (omeprazole) for gastroprotection; aspirin dose ≤ 100 mg/d.
Mechanism: Amiodarone inhibits CYP2C9 (the main enzyme for S-warfarin) as well as CYP3A4 and CYP1A2. The effect increases over 1–7 wk (long amiodarone T1/2 ~ 60 days).
Mechanism: Clarithromycin inhibits CYP3A4 (R-warfarin) and CYP1A2; with long-term therapy it also eliminates the intestinal flora that synthesizes vitamin K2.
Clinical effect: INR ↑ 2–4×; gum bleeding, hematuria, GI bleeding.
Management: Prefer azithromycin (smaller effect on CYP). If clarithromycin is necessary: reduce warfarin by 25%, INR every 3 days.
Source: Lexicomp 2024; Indiana University P450 Table
Mechanism: Vitamin K1 (phylloquinone) directly bypasses the warfarin blockade of VKORC1 and restores the synthesis of factors II/VII/IX/X.
Clinical effect: Pharmacodynamic antagonism: decreased INR, risk of thrombosis. Used therapeutically to reverse warfarin overdose.
Management: Patients on warfarin must maintain a consistent intake of green vegetables (~ 90–120 µg/d). Vit. K 1–10 mg PO/IV as an antidote for INR > 10 or bleeding.
Mechanism: Rifampin is the most potent inducer of CYP2C9, CYP3A4 and CYP1A2 (PXR). 5–7-fold acceleration of the metabolism of both warfarin enantiomers.
Mechanism: 5-FU and capecitabine inhibit CYP2C9, limiting S-warfarin metabolism. The effect is delayed by 4–6 wk and persists for 1–3 months after discontinuation.
Clinical effect: INR ↑ 4–6× toward the end of the chemotherapy cycle; severe bleeding.
Management: Switch to LMWH for the duration of chemotherapy; if warfarin is continued — weekly INR, dose reduction by 50%.
Mechanism: Cimetidine nonspecifically inhibits CYP1A2, CYP2C9, CYP2D6, CYP3A4 — a broad-spectrum inhibitor. The effect on warfarin is mainly via CYP2C9.
Clinical effect: INR ↑ 1.5–2×; risk of bleeding.
Management: Prefer ranitidine/famotidine (H2) or a PPI (e.g., pantoprazole) as alternatives without a CYP effect. INR after 5–7 days.
Mechanism: Early phase: phenytoin displaces warfarin from albumin + inhibits CYP2C9 → INR ↑. Late phase: CYP2C9 induction → INR ↓. Phenytoin itself is a CYP2C9 substrate — warfarin raises its concentration.
Clinical effect: Biphasic: bleeding (1–2 wk) → followed by thrombosis (3–6 wk). Phenytoin toxicity (nystagmus, ataxia).
Management: INR and phenytoin level weekly for 6 wk. Consider an alternative (levetiracetam).
Source: Hansten & Horn 2024; Indiana University P450 Table
Mechanism: Acetaminophen at cumulative doses > 2 g/d for ≥ 7 days inhibits the vitamin K cycle (disrupts warfarin metabolism via NAPQI and VKORC1 inhibition).
Hansten, Philip D., and John R. Horn. 2024. "The Top 100 Drug Interactions: A Guide to Patient Management." H&H Publications.
Stockley, Ivan H., ed. 2021. "Stockley's Drug Interactions." 12th ed. Pharmaceutical Press.
Indiana University. 2024. "P450 Drug Interaction Table." https://drug-interactions.medicine.iu.edu/.
Lexicomp. 2024. "Lexicomp Drug Interactions Database." Wolters Kluwer.
U.S. FDA. 2023. "Drug Development and Drug Interactions Table of Substrates, Inhibitors and Inducers." https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.
Goldfrank, Lewis R., et al. 2019. "Goldfrank's Toxicologic Emergencies." 11th ed. McGraw-Hill (rozdz. Drug Interactions — synergie + antagonizmy w zatruciach mieszanych).
Olson, Kent R., et al. 2018. "Poisoning & Drug Overdose." 7th ed. McGraw-Hill (clinical management of interactions in overdose).
Rosenstock, Linda, et al. 2005. "Textbook of Clinical Occupational and Environmental Medicine." 2nd ed. Elsevier Saunders (occupational + drug exposure interakcje).
Lippmann, Morton. 2009. "Environmental Toxicants: Human Exposures and Their Health Effects." 3rd ed. Wiley (modulation of CYP3A4/CYP2D6 by environmental exposures).
Hayes, Wallace, and Claire L. Kruger, eds. 2014. "Hayes' Principles and Methods of Toxicology." 6th ed. CRC Press (in vitro screening DDI: rola P-gp, BCRP).
📜 Patents (public metadata)
no data
No public patent metadata was found for this substance in Crossref / OpenAlex at this time. Data will be updated automatically after the next cache refresh (24h).
📚 References (Chicago Author-Date) — click to expand
et al.. (2026). "Warfarin Patient Self-Management in the US Health Care System: A Nonrandomized Clinical Trial.". https://doi.org/10.1001/jamanetworkopen.2026.2627
et al.. (2026). "Warfarin-GPRP: Development and Evaluation of a Novel Warfarin-Based Peptide Conjugate for Enhanced Anticoagulant Activity.". https://doi.org/10.1021/acsomega.5c09582
et al.. (2026). "A Descriptive Analysis of Potential Warfarin-NSAID Interactions in Dental Prescribing in Minas Gerais, Brazil, 2011-2021.". https://doi.org/10.3390/healthcare14101326
(2026). "Warfarin-Induced Developmental Toxicity: Insights into Embryogenesis, Teratogenicity, and Molecular Pathways". https://doi.org/10.20944/preprints202606.1173.v1
(2026). "A reproducible rat model for warfarin studies: Prothrombin time assessment with minimal blood using the CoaguChek XS and determination of an effective warfarin dosage.". https://doi.org/10.17221/4/2026-vetmed
et al.. (2026). "Pooled estimate of anticoagulation control with warfarin therapy among adult patients in Ethiopia: a systematic review and meta-analysis.". https://doi.org/10.1186/s12959-026-00865-6
(2026). "Factors Affecting the Time in Therapeutic Range of Warfarin Anticoagulation Therapy in Patients with Atrial Fibrillation.". https://doi.org/10.1177/10760296251414128
et al.. (2026). "Causal Effects of Atrial Fibrillation and Warfarin Use on Osteoporosis Risk: A Two-Sample Mendelian Randomization Analysis.". https://doi.org/10.1155/ijog/7863262
(2026). "Treatment Stability of Warfarin and Acenocoumarol in Patients With Mechanical Heart Valves and Atrial Fibrillation: A One-Year Cohort Study.". https://doi.org/10.5644/ama2006-124.497
et al.. (2026). "Development of a Clinical Decision Support Chatbot to Improve Access to Dental Clinical Practice Guidelines for Warfarin-Treated Patients.". https://doi.org/10.3233/shti260895
et al.. (2026). "Narrative Review of Management Strategies and Risk Mitigation for Gastrointestinal Bleeding in Atrial Fibrillation Patients Receiving Warfarin.". https://doi.org/10.1177/10760296251410932
et al.. (2026). "Persimmon-induced excessive anticoagulation in a patient with mechanical heart valves receiving warfarin therapy: A case report.". https://doi.org/10.1097/md.0000000000047861
et al.. (2026). "Warfarin-Durian interaction: A case study bridging clinical outcomes and metabolic profiling through metabolomics.". https://doi.org/10.1016/j.toxrep.2026.102232
Shota Torii, Tomoya Narita, Aya Torii-Goto et al.. (2026). "Prolongation of prothrombin time-international normalized ratio by concomitant use of warfarin and combination therapy with lenvatinib and pembrolizumab in a patient with renal cell carcinoma on dialysis: a case report". Journal of Pharmaceutical Health Care and Sciences. https://doi.org/10.1186/s40780-026-00598-8
Pitchapong Kositchaiwat, Ubonwan Sapoo, Nutthada Areepium et al.. (2026). "Factors Associated With Time in Therapeutic Range Among Thai Patients with Non-valvular Atrial Fibrillation Taking Warfarin: Development of AHfHDP Score". Clinical and Applied Thrombosis/Hemostasis. https://doi.org/10.1177/10760296261480894
et al.. (2025). "Machine Learning for Warfarin Therapy: A Systematic Review.". https://doi.org/10.3390/ph18101544
(2025). "Rebound warfarin toxicity presenting with spontaneous hemopericardium in cardiac tamponade: a case report.". https://doi.org/10.1186/s12245-025-01037-5
(2025). "Warfarin-Linezolid Interaction: A Case of Severe Coagulopathy.". https://doi.org/10.1155/crdi/5132611
Sunil Kumar Das. (2024). "Knowledge of warfarin among patients on warfarin therapy, using anticoagulant knowledge assessment tool, in Patan Hospital". Journal of General Practice and Emergency Medicine of Nepal. https://doi.org/10.59284/jgpeman291
Dalia Ibrahim, Sohair Albakari, Mohamed Abdelbasit et al.. (2024). "Assessment of Quality of Life, Anxiety, And Depression Via WHOQOL-BREF, And HADS Among Egyptian Patients on Warfarin Therapy: A Cross-Sectional Study.". Zagazig University Medical Journal. https://doi.org/10.21608/zumj.2024.279308.3309
World Intellectual Property Organization. 2024. "Patent Cooperation Treaty (PCT)." https://www.wipo.int/pct/.
U.S. Patent and Trademark Office. 2024. "USPTO Patent Public Search." https://ppubs.uspto.gov/.
European Patent Office. 2024. "Espacenet Patent Search." https://worldwide.espacenet.com/.
Newman, David J., and Gordon M. Cragg. 2020. "Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019." Journal of Natural Products 83 (3): 770-803.
Davies, Mark, Michał Nowotka, George Papadatos, et al. 2015. "ChEMBL Web Services: Streamlining Access to Drug Discovery Data and Utilities." Nucleic Acids Research 43 (W1): W612-W620.
Bickerton, G. Richard, Gaia V. Paolini, Jérémy Besnard, Sorel Muresan, and Andrew L. Hopkins. 2012. "Quantifying the Chemical Beauty of Drugs." Nature Chemistry 4 (2): 90-98.
Meanwell, Nicholas A. 2011. "Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design." Journal of Medicinal Chemistry 54 (8): 2529-2591.
Ertl, Peter, and Ansgar Schuffenhauer. 2009. "Estimation of Synthetic Accessibility Score of Drug-Like Molecules Based on Molecular Complexity and Fragment Contributions." Journal of Cheminformatics 1: 8.
Hopkins, Andrew L., and Colin R. Groom. 2002. "The Druggable Genome." Nature Reviews Drug Discovery 1 (9): 727-730.
Allison, John R., and Mark A. Lemley. 1998. "Empirical Evidence on the Validity of Litigated Patents." AIPLA Quarterly Journal 26 (3): 185-275.
Patani, George A., and Edmond J. LaVoie. 1996. "Bioisosterism: A Rational Approach in Drug Design." Chemical Reviews 96 (8): 3147-3176.
Lerner, Josh. 1994. "The Importance of Patent Scope: An Empirical Analysis." RAND Journal of Economics 25 (2): 319-333.
Crystallographic data for 81-81-2 verified against COD (0 diffraction peaks). The 2θ values below allow identification of the polymorphic form by PXRD in the laboratory.
International Centre for Diffraction Data. 2024. PDF-4+ 2024. Newtown Square, PA: ICDD. 🔓
Allen, Frank H. 2002. "The Cambridge Structural Database: a quarter of a million crystal structures and rising." Acta Crystallographica B 58 (3): 380–388. https://doi.org/10.1107/S0108768102003890
Grazulis, Saulius, Adriana Merkys, Antanas Vaitkus, and Daniel Chateigner. 2012. "Computing stoichiometric molecular composition from crystal structures." Journal of Applied Crystallography 45 (6): 1241–1248. https://doi.org/10.1107/S0021889812042185Open Access
Cullity, B. D., and Stuart R. Stock. 2001. Elements of X-Ray Diffraction. 3rd ed. Upper Saddle River, NJ: Prentice Hall.
Jenkins, Ron, and Robert L. Snyder. 1996. Introduction to X-Ray Powder Diffractometry. New York: Wiley-Interscience. https://doi.org/10.1002/9781118520949
Giacovazzo, Carmelo, Hugo L. Monaco, Giuseppe Artioli, Davide Viterbo, Marco Milanesio, Gastone Gilli, Paola Gilli, Giuseppe Zanotti, Giampiero Ferraris, and Mario Catti. 2011. Fundamentals of Crystallography. 3rd ed. Oxford: Oxford University Press.
Dinnebier, Robert E., and Simon J. L. Billinge, eds. 2008. Powder Diffraction: Theory and Practice. Cambridge: Royal Society of Chemistry. https://doi.org/10.1039/9781847558237
United States Pharmacopeia. 2024. "Chapter <941> Characterization of Crystalline and Partially Crystalline Solids by X-Ray Powder Diffraction (XRPD)." USP-NF. Rockville, MD: USP. 🔓
FAQ — frequently asked questions about PXRD
What is the 2θ angle in PXRD?
2θ is the angle between the incident beam and the diffracted beam, measured in degrees. Bragg's law (nλ = 2d·sinθ) relates the diffraction angle to the d-spacing between lattice planes. For Cu Kα (λ=1.54056 Å) typical peaks lie in the 5–70° range. Each peak corresponds to a different family of hkl planes.
What is the R-factor in crystallography?
The R-factor (residual factor) measures the agreement of a structural model with experimental data: R = Σ|Fo-Fc|/ΣFo. The lower it is, the better the quality of the structure. Values < 0.05 = high quality (the five per cent rule). Values > 0.10 suggest problems with the model or with the data. The R-factor is a standard quality criterion in the CSD and COD databases.
What is PXRD and what is it used for?
PXRD (Powder X-Ray Diffraction) is an analytical technique in which X-rays are diffracted by the atoms of a crystal. The diffraction pattern (2θ angles and intensities) is unique to every crystalline substance and to each of its polymorphic forms — it acts as the crystal's "fingerprint". It is used to identify phases, purity and the polymorphic form of a sample.
Why is the polymorphic form important for the pharmaceutical industry?
Different polymorphic forms of the same substance can have drastically different solubility, and through that different bioavailability of the drug. The famous case: ritonavir (Abbott, 1998) — Form II appeared during production, was 50% less soluble than Form I, which caused the product to be withdrawn and losses of ~250 million USD. The pharmacopoeias (USP, PhEur) require the polymorphic form to be specified.
Have a blog, forum or scientific service? Embed the interactive 3D molecule on your website — every reader will see it, with a link below to the safety data sheet for that substance.
🔗 HTML iframe code (easiest — works everywhere)
Copy and paste into your site's HTML editor:
Adjust width and height to your layout.
⚙ WordPress Shortcode (for other shops with MOL-GOD)
🌐 Direct link (for emails, chats, LinkedIn, Twitter)
When you share the link, Facebook/LinkedIn/Discord will automatically fetch the image preview:
📋 License: The embed keeps a backlink to MolGod (required — the shop is the data source). Chemical data comes from PubChem (CC0 — public domain). The embed is FREE for educational, commercial and hobby use.
📚 REFERENCES (Aggregate bibliography, Chicago Author-Date) 78 items
All scientific sources cited in the accordions above for CAS 81-81-2. Format: Chicago Manual of Style 17th ed., Author-Date system.
AIST. n.d. Spectral Database for Organic Compounds (SDBS): CAS 81-81-2. Tsukuba, Japan: National Institute of Advanced Industrial Science and Technology. https://sdbs.db.aist.go.jp/.
Linstrom, Peter J., and William G. Mallard, eds. n.d. NIST Chemistry WebBook: NIST Standard Reference Database Number 69. Gaithersburg, MD: National Institute of Standards and Technology. https://doi.org/10.18434/T4D303.
PubChem. n.d. PubChem Compound Summary: CAS 81-81-2. Bethesda, MD: National Center for Biotechnology Information (NCBI), National Library of Medicine. https://pubchem.ncbi.nlm.nih.gov/#query=81-81-2.
European Chemicals Agency (ECHA). 2024. "Annex VI to Regulation (EC) No 1272/2008 (CLP) — Harmonised Classification and Labelling." ECHA, Helsinki / Official Journal of the European Union. https://echa.europa.eu/regulations/clp/clp-classification.
National Institute for Occupational Safety and Health (NIOSH). 2017. "Recommendations for Chemical Protective Clothing: A Companion to the NIOSH Pocket Guide." U.S. Department of Health & Human Services / CDC. https://www.cdc.gov/niosh/ncpc/default.html.
Connors, Kenneth A., Gordon L. Amidon, and Valentino J. Stella. 1986. Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists, 2nd ed.. New York: Wiley. https://doi.org/10.1002/0471734683.
Rumble, John R., ed. 2019. CRC Handbook of Chemistry and Physics: 100th Edition. Boca Raton, FL: CRC Press. https://hbcp.chemnetbase.com/.
Stefanis, Emmanuel, and Costas Panayiotou. 2008. "Prediction of Hansen Solubility Parameters with a New Group-Contribution Method." International Journal of Thermophysics 29: 568-585. https://doi.org/10.1007/s10765-008-0415-z.
Stoll, Vincent S., and John S. Blanchard. 1990. "Buffers: Principles and Practice: In Methods in Enzymology, vol. 182." San Diego: Academic Press. https://doi.org/10.1016/0076-6879(90)82008-P.
European Parliament. 2008. "Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging of Substances and Mixtures (CLP)." Official Journal of the European Union L 353: 1–1355.
United Nations. 2021. Globally Harmonized System of Classification and Labelling of Chemicals (GHS). 9th revised ed. ST/SG/AC.10/30/Rev.9. New York and Geneva: United Nations. https://unece.org/ghs-rev9-2021.
United States Pharmacopeial Convention. 2024. "USP <621> Chromatography." In United States Pharmacopeia and National Formulary, USP 47-NF 42. Rockville, MD: USP. https://www.uspnf.com/.
International Organization for Standardization. 2017. "ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories." Geneva: ISO. https://www.iso.org/standard/66912.html.
Kolthoff, Izaak Maurits, and Philip J. Elving, eds. 1978. Treatise on Analytical Chemistry, Part I: Theory and Practice. 2nd ed. New York: Wiley-Interscience.
Skoog, Douglas A., F. James Holler, and Stanley R. Crouch. 2018. Principles of Instrumental Analysis. 7th ed. Boston: Cengage Learning.
Christian, Gary D., Purnendu K. Dasgupta, and Kevin A. Schug. 2014. Analytical Chemistry. 7th ed. Hoboken, NJ: Wiley.
International Organization for Standardization. 1994. "ISO 5725-2:1994 Accuracy (Trueness and Precision) of Measurement Methods and Results — Part 2: Basic Method for the Determination of Repeatability and Reproducibility of a Standard Measurement Method." Geneva: ISO. https://www.iso.org/standard/11834.html.
Heckert, N. A., and J. J. Filliben. 2003. "NIST/SEMATECH e-Handbook of Statistical Methods." NIST Handbook 151. Gaithersburg, MD: National Institute of Standards and Technology. https://www.itl.nist.gov/div898/handbook/.
Grubbs, Frank E. 1950. "Sample Criteria for Testing Outlying Observations." Annals of Mathematical Statistics 21 (1): 27–58.
Dixon, Wilfrid J. 1950. "Analysis of Extreme Values." Annals of Mathematical Statistics 21 (4): 488–506.
Snedecor, George W., and William G. Cochran. 1989. Statistical Methods. 8th ed. Ames, IA: Iowa State University Press.
Student [William Sealy Gosset]. 1908. "The Probable Error of a Mean." Biometrika 6 (1): 1–25.
International Organization for Standardization. 2005. "ISO 3534-1:2006 Statistics — Vocabulary and Symbols — Part 1: General Statistical Terms and Terms Used in Probability." Geneva: ISO. https://www.iso.org/standard/40145.html.
Thompson, Michael, Stephen L. R. Ellison, and Roger Wood. 2002. "Harmonized Guidelines for Single-Laboratory Validation of Methods of Analysis." Pure and Applied Chemistry 74 (5): 835–855.
United Nations Economic Commission for Europe. 2024. European Agreement Concerning the International Carriage of Dangerous Goods by Road (ADR), Applicable as from 1 January 2025 (ECE/TRANS/352). Geneva: UNECE. https://unece.org/transport/dangerous-goods/adr-2025-edition.
Ministerstwo Klimatu i Środowiska Rzeczypospolitej Polskiej. 2020. "Rozporządzenie Ministra Klimatu z dnia 2 stycznia 2020 r. w sprawie katalogu odpadów." Dziennik Ustaw RP 2020 poz. 10. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20200000010. National rules — Poland
Główny Inspektorat Ochrony Środowiska (GIOŚ). 2024. "Baza Danych O Odpadach (BDO) — System rejestracji firm utylizacyjnych." Ministerstwo Klimatu i Środowiska. https://bdo.mos.gov.pl/. National rules — Poland
International Organization for Standardization. 2017. "ISO/IEC 17025:2017 General requirements for the competence of testing and calibration laboratories." ISO. https://www.iso.org/standard/66912.html.
World Health Organization. 2010. "WHO Good Manufacturing Practices for Pharmaceutical Products: Main Principles (WHO Technical Report Series No. 957, Annex 3)." WHO Press. https://www.who.int/publications/m/item/trs957-annex3.
Pharmaceutical Inspection Co-operation Scheme (PIC/S). 2021. "Guide to Good Manufacturing Practice for Medicinal Products PE 009-15." PIC/S Secretariat, Geneva. https://picscheme.org/en/publications.
